MAIA Biotechnology, Inc.
  • About
    • About Us
    • Management
    • Board of Directors
    • Scientific Advisors
    • Advisors
    • Careers
  • Programs
    • Pipeline
    • Ateganosine (THIO) Program
    • Second-Generation Programs
    • Publications
  • Partners
  • Investors
  • Contact
  • Menu Menu
  • x
  • LinkedIn

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Management Team
    • Analyst Coverage
    • Presentations
    • Contacts
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • IR Calendar
  • Email Alerts
Nov 15, 2023 9:35am EST

MAIA Biotechnology Announces $4 Million Registered Direct Offering

Nov 10, 2023 7:01am EST

FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma

Nov 07, 2023 8:15am EST

MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO

Oct 30, 2023 8:41am EDT

MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO

Oct 24, 2023 8:00am EDT

MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial

Oct 19, 2023 8:35am EDT

MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023

Oct 17, 2023 8:01am EDT

MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023

Oct 12, 2023 9:20am EDT

MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer

Oct 10, 2023 11:15am EDT

MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients

Oct 10, 2023 8:01am EDT

MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas

  • arrow_back
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© Copyright 2025 - MAIA Biotechnology, Inc.     312.416.8592     |     info@maiabiotech.com     |     Terms of Use    |     Privacy Policy    |     Cookies Policy